# The Safety and Tolerability Study With ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease

> **NCT06024265** · EARLY_PHASE1 · COMPLETED · sponsor: **ExoRNA Bioscience** · enrollment: 10 (actual)

## Conditions studied

- Huntington Disease

## Interventions

- **DRUG:** ER2001 injection

## Key facts

- **NCT ID:** NCT06024265
- **Lead sponsor:** ExoRNA Bioscience
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-04
- **Primary completion:** 2025-01-31
- **Final completion:** 2025-09-04
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06024265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06024265, "The Safety and Tolerability Study With ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06024265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*